The metabolic profile of intrahepatic cholestasis of pregnancy is associated with impaired glucose tolerance, dyslipidemia, and increased fetal growth

Diabetes Care

Volumn 38, Issue 2, 2015, Pages 243-248

  Martineau, Marcus G ^a,b   Raker, Christina ^c   Dixon, Peter H ^a,d   Chambers, Jenny ^a   Machirori, Mavis ^a   King, Nicole M ^a   Hooks, Melissa L ^b   Manoharan, Ramya ^a   Chen, Kenneth ^b   Powrie, Raymond ^b   Williamson, Catherine ^a,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b BROWN UNIVERSITY   (United States)

^c WOMEN AND INFANTS HOSPITAL   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CHOLESTEROL; GLUCOSE BLOOD LEVEL; LIPID;

ADULT; ARTICLE; BIRTH WEIGHT; BLOOD GLUCOSE MONITORING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS GLUCOSE MONITORING; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ETHNICITY; FEMALE; FETUS GROWTH; GENDER; GESTATIONAL AGE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HORMONE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INTRAHEPATIC CHOLESTASIS; INTRAHEPATIC CHOLESTASIS OF PREGNANCY; LARGE FOR GESTATIONAL AGE; LIPID METABOLISM; PREGNANCY; PREGNANCY DIABETES MELLITUS; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; UNITED STATES; UNIVERSITY HOSPITAL; BLOOD; CLINICAL TRIAL; FETUS DEVELOPMENT; GLUCOSE INTOLERANCE; MACROSOMIA; MALE; METABOLIC SYNDROME X; METABOLISM; METABOLOME; MULTICENTER STUDY; PHYSIOLOGY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME;

ADULT; BIRTH WEIGHT; BLOOD GLUCOSE; CHOLESTASIS, INTRAHEPATIC; CHOLESTEROL; DIABETES, GESTATIONAL; DYSLIPIDEMIAS; FEMALE; FETAL DEVELOPMENT; FETAL MACROSOMIA; GESTATIONAL AGE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; METABOLOME; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 84921905803     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2143     Document Type: Article

References (45)

1. Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol 2009;15:2049-2066
2. Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol 2014;124:120-133
3. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology 2004;40:467-474
4. Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology 2014;59:1482-1491
5. Lee RH, Kwok KM, Ingles S, et al. Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy. Am J Perinatol 2008;25:341-345
6. Castaño G, Lucangioli S, Sookoian S, et al. Bile acid profiles by capillary electrophoresis in intrahepatic cholestasis of pregnancy. Clin Sci (Lond) 2006;110:459-465
7. Pascual MJ, Serrano MA, El-Mir MY, Macias RI, Jiménez F, Marin JJ. Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clin Sci (Lond) 2002;102:587-593
8. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-1109
9. Lambert G, Amar MJ, Guo G, Brewer HB Jr, Gonzalez FJ, Sinal CJ. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003;278:2563-2570
10. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferatoractivated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003;17:259-272
11. Cariou B, Staels B. FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci 2007;28:236-243
12. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009;10:167-177
13. Baliutavičieně D, Zubruvieně N, Zalinkevičius R. Pregnancy outcome in cases of intrahepatic cholestasis of pregnancy. Int J Gynaecol Obstet 2011;112:250-251
14. Wikström Shemer E, Marschall HU, Ludvigsson JF, Stephansson O. Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. BJOG 2013;120:717-723
15. Dann AT, Kenyon AP, Wierzbicki AS, Seed PT, Shennan AH, Tribe RM. Plasma lipid profiles of women with intrahepatic cholestasis of pregnancy. Obstet Gynecol 2006;107:106-114
16. Nikkilä K, Riikonen S, Lindfors M, Miettinen TA. Serum squalene and noncholesterol sterols before and after delivery in normal and cholestatic pregnancy. J Lipid Res 1996;37:2687-2695
17. Martineau M, Raker C, Powrie R, Williamson C. Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes. Eur J Obstet Gynecol Reprod Biol 2014;176:80-85
18. Gluckman PD, Hanson MA, Bateson P, et al. Towards a new developmental synthesis: adaptive developmental plasticity and human disease. Lancet 2009;373:1654-1657
19. Papacleovoulou G, Abu-Hayyeh S, Nikolopoulou E, et al. Maternal cholestasis during pregnancy programs metabolic disease in offspring. J Clin Invest 2013;123:3172-3181
20. Wójcicka-Jagodzínska J, Kuczyńska-Sicínska J, Czajkowski K, Smolarczyk R. Carbohydratemetabolism in the course of intrahepatic cholestasis in pregnancy. Am J Obstet Gynecol 1989;161:959-964
21. Hernandez TL, Barbour LA. A standard approach to continuous glucose monitor data in pregnancy for the study of fetal growth and infant outcomes. Diabetes Technol Ther 2013;15:172-179
22. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-1304
23. American College of Obstetricians and Gynecologists. Practice bulletin no. 137: gestational diabetes mellitus. Obstet Gynecol 2013;122(2 Pt 1):406-416
24. Gardosi J, Chang A, Kalyan B, Sahota D, Symonds EM. Customised antenatal growth charts. Lancet 1992;339:283-287
25. Johnson P. Studies in cholestasis of pregnancy with special reference to lipids and lipoproteins. Acta Obstet Gynecol Scand Suppl 1973;27:1-80
26. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 2009;30:570-580
27. Sharma R, Long A, Gilmer JF. Advances in bile acid medicinal chemistry. Curr Med Chem 2011;18:4029-4052
28. Glantz A, Reilly SJ, Benthin L, Lammert F, Mattsson LA, Marschall HU. Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology 2008;47:544-551
29. Abu-Hayyeh S, Papacleovoulou G, Lovgren-Sandblom A, et al. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a pro-cholestatic phenotype. Hepatology 2013;57:716-726
30. Cariou B, Van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006;281:11039-11049
31. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006;103:1006-1011
32. Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 2004;279:23158-23165
33. Shen H, Zhang Y, Ding H, et al. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell Physiol Biochem 2008;22:1-14
34. Renga B, Mencarelli A, Vavassori P, Brancaleone V, Fiorucci S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta 2010;1802:363-372
35. Düfer M, Hörth K, Wagner R, et al. Bile acids acutely stimulate insulin secretion of mouse b-cells via farnesoid X receptor activation and K (ATP) channel inhibition. Diabetes 2012;61:1479-1489
36. Seyer P, Vallois D, Poitry-Yamate C, et al. Hepatic glucose sensing is required to preserve b cell glucose competence. J Clin Invest 2013;123:1662-1676
37. Parker HE, Wallis K, Le Roux CW, Wong KY, Reimann F, Gribble FM. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol 2012;165:414-423
38. Jansen PL. A new life for bile acids. J Hepatol 2010;52:937-938
39. Murakami M, Une N, Nishizawa M, Suzuki S, Ito H, Horiuchi T. Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects. Springerplus 2013;2:20
40. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999;10:245-257
41. Pedersen J. Diabetes and pregnancy; blood sugar of newborn infants during fasting and glucose administration. Nord Med 1952;47:1049
42. Metzger BE, Lowe LP, Dyer AR, et al.; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002
43. Herrera E, Ortega-Senovilla H. Disturbances in lipid metabolism in diabetic pregnancy - Are these the cause of the problem? Best Pract Res Clin Endocrinol Metab 2010;24:515-525
44. Malcolm J. Through the looking glass: gestational diabetes as a predictor of maternal and offspring long-term health. Diabetes Metab Res Rev 2012;28:307-311
45. Yessoufou A, Moutairou K. Maternal diabetes in pregnancy: early and long-term outcomes on the offspring and the concept of "metabolic memory." Exp Diabetes Res 2011;2011:218598